Fig. 6.

Ab29 increases microglial responses to amyloid plaques in vivo. a. schematic diagram showing the stereotaxic injection of hMGLs and Ab29 in 5XFAD mice. The hMGLs were injected into the lateral ventricles through stereotaxic injections together with antibodies. The 5XFAD mice were sacrificed 96 hours after the injection and brains were harvested for analysis. b. Antibody concentrations in perfused 5XFAD at the experiment endpoint as described in a. n = 5 independent mice. c. Representative amyloid plaque-microglia co-localization immunofluorescence staining of 5-month-old 5XFAD mice cortex as treated in a. Scale bar = 20 μm. IBA1, microglia marker; 6E10, amyloid plaque marker; the nucleus is labeled by TO-PRO-3. d. Quantification of IBA1 area within 30 μm of amyloid plaques in the cortex of mice treated as described in a. n = 5 independent mice. e. Representative amyloid plaque-CD68 co-localization immunofluorescence staining of the cortex of 5XFAD mice treated as described in a. CD68, microglia phagocytic marker; the nucleus is labeled by TO-PRO-3. Scale bar = 20 μm. f. Quantification of CD68 area within 30 μm of amyloid plaques in the cortex of mice treated as described in a. n = 5 independent mice. g. Quantification of Aβ co-localized with CD68 per plaque in the cortex of mice treated as described in a. n = 5 independent mice. For all the data presented, bar graphs with error bars represent mean ± SD. For the statistical analysis, *** P < 0.001, two-tailed Student t-test